<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antipsychotics for fibromyalgia in adults - Walitt, B - 2016 | Cochrane Library</title> <meta content="Antipsychotics for fibromyalgia in adults - Walitt, B - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011804.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antipsychotics for fibromyalgia in adults - Walitt, B - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011804.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011804.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antipsychotics for fibromyalgia in adults" name="citation_title"/> <meta content="Brian Walitt" name="citation_author"/> <meta content="Petra Klose" name="citation_author"/> <meta content="University of Duisburg‐Essen" name="citation_author_institution"/> <meta content="Nurcan Üçeyler" name="citation_author"/> <meta content="University of Würzburg" name="citation_author_institution"/> <meta content="Tudor Phillips" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="whaeuser@klinikum-saarbruecken.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011804.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011804.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011804.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011804.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amitriptyline [therapeutic use]; Analgesics, Non‐Narcotic [therapeutic use]; Antipsychotic Agents [*therapeutic use]; Fibromyalgia [*drug therapy]; Quetiapine Fumarate [*therapeutic use]; Randomized Controlled Trials as Topic; Sleep Wake Disorders [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011804.pub2&amp;doi=10.1002/14651858.CD011804.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011804\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011804\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011804.pub2",title:"Antipsychotics for fibromyalgia in adults",firstPublishedDate:"Jun 2, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011804.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011804.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011804.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011804.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011804.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011804.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011804.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011804.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011804.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011804.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5174 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011804.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/appendices#CD011804-sec-0123"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/table_n/CD011804StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/table_n/CD011804StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antipsychotics for fibromyalgia in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#CD011804-cr-0002">Brian Walitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#CD011804-cr-0003">Petra Klose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#CD011804-cr-0004">Nurcan Üçeyler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#CD011804-cr-0005">Tudor Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information#CD011804-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information/en#CD011804-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011804.pub2">https://doi.org/10.1002/14651858.CD011804.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011804-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011804-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011804-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011804-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011804-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011804-abs-0001" lang="en"> <section id="CD011804-sec-0001"> <h3 class="title" id="CD011804-sec-0001">Background</h3> <p>This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well‐defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co‐exists with sleep problems and fatigue. It affects approximately 2% of the general population. Up to 70% of patients with fibromyalgia meet the criteria for a depressive or anxiety disorder. People often report high disability levels and poor health‐related quality of life. Drug therapy focuses on reducing key symptoms and disability, and improving health‐related quality of life. Antipsychotics might reduce fibromyalgia and associated mental health symptoms. </p> </section> <section id="CD011804-sec-0002"> <h3 class="title" id="CD011804-sec-0002">Objectives</h3> <p>To assess the efficacy, tolerability and safety of antipsychotics in fibromyalgia in adults. </p> </section> <section id="CD011804-sec-0003"> <h3 class="title" id="CD011804-sec-0003">Search methods</h3> <p>We searched CENTRAL (2016, Issue 4), MEDLINE and EMBASE to 20 May 2016, together with reference lists of retrieved papers and reviews and two clinical trial registries. We also contacted trial authors. </p> </section> <section id="CD011804-sec-0004"> <h3 class="title" id="CD011804-sec-0004">Selection criteria</h3> <p>We selected controlled trials of at least four weeks duration of any formulation of antipsychotics used for the treatment of fibromyalgia in adults. </p> </section> <section id="CD011804-sec-0005"> <h3 class="title" id="CD011804-sec-0005">Data collection and analysis</h3> <p>We extracted the data from all included studies and two review authors independently assessed study risks of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. We derived first tier evidence from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention‐to‐treat analysis without imputation for drop‐outs, at least 200 participants in the comparison, eight to 12 weeks duration, parallel design), second tier evidence from data that failed to meet one or more of these criteria and that we considered at some risk of bias but with adequate numbers in the comparison, and third tier evidence from data involving small numbers of participants that we considered very likely to be biased or used outcomes of limited clinical utility, or both. We rated the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD011804-sec-0006"> <h3 class="title" id="CD011804-sec-0006">Main results</h3> <p>We included a total of four studies with 296 participants.</p> <p>Three studies with 206 participants compared quetiapine, an atypical (second‐generation) antipsychotic, with placebo. One study used a cross‐over design and two studies a parallel‐group design. Study duration was eight or 12 weeks. Quetiapine was used in all studies with a bedtime dosage between 50 and 300 mg/day. All studies had one or more sources of potential major bias and we judged them to be at moderate risk of bias overall. The primary outcomes in this review were participant‐reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). </p> <p>Second tier evidence indicated that quetiapine was not statistically superior to placebo in the number of participants with a 50% or more pain reduction (very low quality evidence). No study reported data on PGIC. A greater proportion of participants on quetiapine reported a 30% or more pain reduction (risk difference (RD) 0.12, 95% confidence interval (CI) 0.00 to 0.23; number needed to treat for an additional benefit (NNTB) 8, 95% CI 5 to 100) (very low quality evidence). A greater proportion of participants on quetiapine reported a clinically relevant improvement of health‐related quality of life compared to placebo ( RD 0.18, 95% CI 0.05 to 0.31; NNTB 5, 95% CI 3 to 20) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing sleep problems (standardised mean difference (SMD) ‐0.67, 95% CI ‐1.10 to ‐0.23), depression (SMD ‐0.39, 95% CI ‐0.74 to ‐0.04) and anxiety (SMD ‐0.40, 95% CI ‐0.69 to ‐0.11) (very low quality evidence). Quetiapine was statistically superior to placebo in reducing the risk of withdrawing from the study due to a lack of efficacy (RD ‐0.14, 95% CI ‐0.23 to ‐0.05) (very low quality evidence). There was no statistically significant difference between quetiapine and placebo in the proportion of participants withdrawing due to adverse events (tolerability) (very low quality evidence), in the frequency of serious adverse events (safety) (very low quality evidence) and in the proportion of participants reporting dizziness and somnolence as an adverse event (very low quality evidence). In more participants in the quetiapine group a substantial weight gain was noted (RD 0.08, 95% CI 0.02 to 0.15; number needed to treat for an additional harm (NNTH) 12, 95% CI 6 to 50) (very low quality evidence). We downgraded the quality of evidence by three levels to a very low quality rating because of limitations of study design, indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). </p> <p>One parallel design study with 90 participants compared quetiapine (50 to 300 mg/day flexible at bedtime) to amitriptyline (10 to 75 mg/day flexible at bedtime). The study had three major risks of bias and we judged it to be at moderate risk of bias overall. We downgraded the quality of evidence by two levels to a low quality rating because of indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients were analysed). Third tier evidence indicated no statistically significant differences between the two drugs. Both drugs did not statistically significantly differ in the reduction of average scores for pain, fatigue, sleep problems, depression, anxiety and for limitations of health‐related quality of life and in the proportion of participants reporting dizziness, somnolence and weight gain as a side effect (low quality evidence). Compared to amitriptyline, more participants left the study due to adverse events (low quality evidence). No serious adverse events were reported (low quality evidence). </p> <p>We found no relevant study with other antipsychotics than quetiapine in fibromyalgia.</p> </section> <section id="CD011804-sec-0007"> <h3 class="title" id="CD011804-sec-0007">Authors' conclusions</h3> <p>Very low quality evidence suggests that quetiapine may be considered for a time‐limited trial (4 to 12 weeks) to reduce pain, sleep problems, depression and anxiety in fibromyalgia patients with major depression. Potential side effects such as weight gain should be balanced against the potential benefits in shared decision making with the patient. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011804-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011804-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011804-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011804-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011804-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011804-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011804-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011804-abs-0003" lang="en"> <h3>Antipsychotics for fibromyalgia symptoms in adults</h3> <p><b>Bottom line</b> </p> <p>Quetiapine may be considered for 4 to 12 weeks to reduce pain, sleep problems, depression and anxiety in fibromyalgia patients with major depression. Potential side effects such as weight gain should be balanced against the potential benefits. </p> <p><b>Background</b> </p> <p>People with fibromyalgia often have chronic (longer than three months) widespread pain, as well as sleep problems, problems with thinking and exhaustion. They often report severe limitations of daily functioning and poor quality of life. Therapies focus on reducing key symptoms and disability, and improving health‐related quality of life. In addition, many patients with fibromyalgia suffer from depression. Medicines used to treat depression can reduce the main symptoms in some people with fibromyalgia. Quetiapine is a drug for the treatment of psychosis (an abnormal condition of the mind described as involving a loss of contact with reality), which is also licensed for the treatment of major depression in some countries. </p> <p><b>Study characteristics</b> </p> <p>In May 2016, we searched for clinical trials in which antipsychotics were used to treat symptoms of fibromyalgia in adults. We found a total of four studies with 298 participants. We found three studies with 208 participants, which were eight and 12 weeks long and compared quetiapine, an antipsychotic, against a fake medication (placebo). One hundred and sixty‐six participants were diagnosed with major depression. We also found one study comprising 90 patients that compared quetiapine to an antidepressant named amitriptyline, which is frequently used in the treatment of fibromyalgia. Five people in this study were diagnosed with major depression. </p> <p><b>Key results and quality of the evidence</b> </p> <p>Quetiapine was not better than a fake medication in achieving a pain reduction of 50% or more (very low quality evidence). Quetiapine was better than the fake medication in achieving a pain reduction of 30% or more, reducing sleep problems, and improving depressed mood and anxiety (very low quality evidence). Quetiapine was better than the fake medication in improving health‐related quality of life. Fewer participants dropped out of the trial due to lack of efficacy with quetiapine than with fake medication (very low quality evidence). There was no difference in tolerability and safety between quetiapine and a fake medication (very low quality evidence). For some people, quetiapine led to substantial weight gain and somnolence (sleepiness). </p> <p>Quetiapine and amitriptyline (an antidepressant which is frequently used to improve sleep and reduce pain in people with fibromyalgia) did not differ in the reduction of average scores for pain, fatigue, sleep problems, depression, anxiety and for limitations of health‐related quality of life. Both drugs did not differ in the proportion of patients reporting dizziness, somnolence and weight gain as a side effect (low quality evidence). Compared with amitriptyline, more people experienced side effects and left the study due to side effects with quetiapine (low quality evidence). No serious side effects with either drug were reported (low quality evidence). </p> <p>We found no relevant study with other antipsychotics than quetiapine in fibromyalgia.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011804-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011804-sec-0111"></div> <h3 class="title" id="CD011804-sec-0112">Implications for practice</h3> <section id="CD011804-sec-0112"> <section id="CD011804-sec-0113"> <h5 class="title">For people with fibromyalgia</h5> <p>There is no convincing, unbiased, high quality evidence to suggest that the atypical antipsychotic quetiapine is superior to the antidepressant amitriptyline, a standard drug used for the treatment of fibromyalgia (<a href="./references#CD011804-bbs2-0006" title="AblinJ , FitzcharlesMA , BuskilaD , ShirY , SommerC , et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence‐based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence Based Complementary Alternative Medicine2013;2013:485272. ">Ablin 2013</a>). A small number of patients may obtain a minimal clinical or greater benefit from quetiapine in terms of a moderate pain reduction, a reduction of sleep problems, depression and anxiety, and improvement in health‐related quality of life. Adverse events (somnolence, weight gain) may limit its clinical usefulness. We found no relevant study of other antipsychotics than quetiapine in fibromyalgia. </p> </section> <section id="CD011804-sec-0114"> <h5 class="title">For physicians</h5> <p>Antipsychotics are not licensed for fibromyalgia in any country. Quetiapine is licensed for the treatment of major depression in some countries. There is no other current guideline recommendation for the use of any antipsychotic in the management of fibromyalgia (<a href="./references#CD011804-bbs2-0006" title="AblinJ , FitzcharlesMA , BuskilaD , ShirY , SommerC , et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence‐based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence Based Complementary Alternative Medicine2013;2013:485272. ">Ablin 2013</a>). Quetiapine may be considered for a time‐limited trial (4 to 12 weeks) to reduce sleep problems and depression in fibromyalgia patients with major depression if antidepressants such as duloxetine have failed. Duloxetine is approved for the treatment of fibromyalgia in all continents except Europe and for the treatment of major depression in most countries worldwide (<a href="./references#CD011804-bbs2-0030" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292] ">Häuser 2013b</a>). Since relatively few participants achieve a worthwhile response with quetiapine, it is important to establish stopping rules, so that when someone does not respond within a specified time they can be switched to an alternative treatment. This will reduce the number of participants exposed to adverse events in the absence of benefit. </p> </section> <section id="CD011804-sec-0115"> <h5 class="title">For policy‐makers</h5> <p>Since no single treatment is effective in a majority of individuals with fibromyalgia, the relatively small number who benefit may be considered worthwhile, particularly if appropriate stopping rules are in place. </p> </section> <section id="CD011804-sec-0116"> <h5 class="title">For funders</h5> <p>Quetiapine and other atypical antipsychotics with a low risk of weight gain may be worth considering as a potential treatment in fibromyalgia patients with major depression, as there are few proven effective drug treatments. </p> </section> </section> <h3 class="title" id="CD011804-sec-0117">Implications for research</h3> <section id="CD011804-sec-0117"> <section id="CD011804-sec-0118"> <h5 class="title">General</h5> <p>The trials in this review used the last observation carried forward (LOCF) imputation method for study withdrawals, therefore post‐hoc individual participant‐level analyses using baseline observation carried forward (BOCF) would be appropriate to strengthen the findings. </p> <p>Further international studies, which include people with major medical diseases and mental disorders such as anxiety disorders, are necessary to provide external validity of the study findings. </p> </section> <section id="CD011804-sec-0119"> <h5 class="title">Measurement (endpoints)</h5> <p>Responder criteria for a clinically relevant improvement of sleep problems and fatigue should be defined. </p> </section> <section id="CD011804-sec-0120"> <h5 class="title">Comparison between active treatments</h5> <p>Any comparisons in future trials should be made with placebo and other drugs with known efficacy, such as amitriptyline or pregabalin. In addition, studies comparing single therapies (e.g. atypical antipsychotics) versus combination therapies (e.g. atypical antipsychotics and aerobic exercise) are necessary. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011804-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011804-sec-0022"></div> <div class="table" id="CD011804-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antipsychotics compared with placebo for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with fibromyalgia </p> <p><b>Settings:</b> research centres </p> <p><b>Intervention:</b> quetiapine 50 to 300 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD, risk difference and NNTB/NNTH<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 50 % pain relief</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB not calculated because of lack of statistical significance</b> </p> <p><b>RD 0.04</b> <br/> (‐0.02 to 0.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change much or very much improved</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sleep problems</b> </p> <p>(Scale 0 to 21; higher scores indicate more sleep problems) <sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sleep problems in the intervention groups was<br/> <b>0.67 standard deviations lower</b> <br/> (1.1 to 0.23 lower) </p> <p><b>NNTB</b> 4 (2 to 12) </p> <p><b>SMD</b> ‐0.67 (‐1.1 to ‐0.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>(Scale 0 to 50) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the intervention groups was<br/> <b>0.39 standard deviations lower</b> <br/> (0.74 to 0.04 lower) </p> <p><b>NNTB</b> 6 (3 to 53) </p> <p><b>SMD</b> ‐0.39 (‐0.74 to ‐0.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH not calculated because of lack of statistical significance</b> </p> <p><b>RD 0.10</b> <br/> (‐0.06 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH not calculated because of lack of statistical significance</b> </p> <p><b>RR ‐</b>0.00 (‐0.03 to 0.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Substantial weight gain</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH 12 (95% CI 0.02 to 0.15)</b> </p> <p><b>RD 0.08</b> <br/> (0.02 to 0.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the risk ratio of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional benefit; <b>NNTH</b> : number needed to treat for an additional harm; <b>RD:</b> risk difference; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations of study design (&gt; 50% participants in low quality studies). </p> <p><sup>2</sup>Imprecision: fewer than 400 participants. </p> <p><sup>3</sup>Indirectness: patients with major medical diseases and mental disorders, except major depression, were excluded. </p> <p><sup>4</sup>Potvin 2012: baseline score for sleep problems in control group: 12.8 (SD 4.3). Higher scores indicate more sleep problems. </p> <p><sup>5</sup>McIntyre 2014: baseline score for depression 24.6 (SD 11.5). Higher scores indicate more depression. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011804-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011804-sec-0023"></div> <p>This review is based on a template for reviews of drugs used to relieve fibromyalgia symptoms. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD011804-bbs2-0046" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./appendices#CD011804-sec-0124">Appendix 1</a>) and fibromyalgia (<a href="./references#CD011804-bbs2-0042" title="MeaseP , ArnoldLM , ChoyEH , ClauwDJ , CroffordLJ , GlassJ , et al. Fibromyalgia Syndrome Module at OMERACT 9. Journal of Rheumatology2009;36:2318–29. ">Mease 2009</a>). </p> <section id="CD011804-sec-0024"> <h3 class="title" id="CD011804-sec-0024">Description of the condition</h3> <p>Fibromyalgia is defined by the American College of Rheumatology (ACR) 1990 classification criteria as widespread pain that lasts for longer than three months, with tenderness on palpation at 11 or more of 18 specified tender points (<a href="./references#CD011804-bbs2-0076" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160‐72. ">Wolfe 1990</a>). Chronic widespread pain is frequently associated with other symptoms such as poor sleep, fatigue and depression (<a href="./references#CD011804-bbs2-0080" title="WolfeF , WalittBT , HäuserW . What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care &amp; Research2014;66:969‐71. [DOI: 10.1002/acr.22207] ">Wolfe 2014</a>). Patients often report high disability levels and poor quality of life along with extensive use of medical care (<a href="./references#CD011804-bbs2-0032" title="HäuserW , AblinJ , FitzcharlesMA , LittlejohnJ , LucianoJV , et al. Fibromyalgia. Nature Reviews Disease Primers2015;1:15022. [DOI: 10.1038/nrdp.2015.22] ">Häuser 2015a</a>). Fibromyalgia symptoms can be assessed by self report of the patient ‐ via the fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia (so‐called Fibromyalgia Symptom Questionnaire) (<a href="./references#CD011804-bbs2-0078" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology2011;38:1113‐22. ">Wolfe 2011</a>). For a clinical diagnosis, the ACR 1990 classification criteria (<a href="./references#CD011804-bbs2-0076" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160‐72. ">Wolfe 1990</a>) and the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD011804-bbs2-0077" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care &amp; Research2010;62:600‐10. ">Wolfe 2010</a>) can be used. Lacking a specific laboratory test, diagnosis is established by a history of the key symptoms and the exclusion of somatic diseases sufficiently explaining the key symptoms (<a href="./references#CD011804-bbs2-0077" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care &amp; Research2010;62:600‐10. ">Wolfe 2010</a>). The indexing of fibromyalgia within the international classification of diseases is under debate. While some rheumatologists have thought of it as a specific pain disorder and central sensitivity syndrome (<a href="./references#CD011804-bbs2-0013" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311:1547‐55. ">Clauw 2014</a>; <a href="./references#CD011804-bbs2-0081" title="YunusMB . Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism2008;37:339‐52. ">Yunus 2008</a>), recent research points at small fibre pathology in a subgroup of fibromyalgia patients that may be of pathophysiological importance (<a href="./references#CD011804-bbs2-0062" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154:2310‐6. ">Oaklander 2013</a>; <a href="./references#CD011804-bbs2-0083" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel‐SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136:e247. ">Üçeyler 2013a</a>). In psychiatry and psychosomatic medicine, fibromyalgia symptoms are categorised as a functional somatic syndrome, a bodily distress syndrome, a somatic symptom disorder or a somatoform disorder (<a href="./references#CD011804-bbs2-0031" title="HäuserW , HenningsenP . Fibromyalgia syndrome ‐ a somaform disorder?. European Journal of Pain2014;18:1052‐9. ">Häuser 2014</a>). </p> <p>Fibromyalgia is a heterogenous condition. The definite aetiology (causes) of this syndrome remains unknown. A model of interacting biological and psychosocial variables in the predisposition, triggering and development of the chronicity of fibromyalgia symptoms has been suggested (<a href="./references#CD011804-bbs2-0068" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz2012;26:259‐67. ">Sommer 2012</a>). Depression (<a href="./references#CD011804-bbs2-0021" title="ForsethKO , HusbyG , GranJT , FørreO . Prognostic factors for the development of fibromyalgia in women with self‐reported musculoskeletal pain. A prospective study. Journal of Rheumatology1999;26:2458‐67. ">Forseth 1999</a>), genetics (<a href="./references#CD011804-bbs2-0008" title="ArnoldLM , FanJ , RussellIJ , YunusMB , KhanMA , KushnerI , et al. The fibromyalgia family study: a genome‐wide linkage scan study. Arthritis and Rheumatism2013;65:1122‐8. ">Arnold 2013</a>; <a href="./references#CD011804-bbs2-0039" title="LeeYH , ChoiSJ , JiJD , SongGG . Candidate gene studies of fibromyalgia: a systematic review and meta‐analysis. Rheumatology International2012;32:417‐26. ">Lee 2012</a>), obesity combined with physical inactivity (<a href="./references#CD011804-bbs2-0058" title="MorkPJ , VasseljenO , NilsenTI . Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord‐Trøndelag Health Study. Arthritis Care &amp; Research2010;62:611‐7. ">Mork 2010</a>), physical and sexual abuse in childhood (<a href="./references#CD011804-bbs2-0028" title="HäuserW , KossevaM , ÜceylerN , KloseP , SommerC . Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta‐analysis. Arthritis Care &amp; Research2011;63:808‐20. ">Häuser 2011</a>), sleep problems (<a href="./references#CD011804-bbs2-0059" title="MorkPJ , NilsenTI . Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism2012;64:281‐4. ">Mork 2012</a>), and smoking predict future development of fibromyalgia (<a href="./references#CD011804-bbs2-0012" title="ChoiCJ , KnutsenR , OdaK , FraserGE , KnutsenSF . The association between incident self‐reported fibromyalgia and nonpsychiatric factors: 25‐years follow‐up of the Adventist Health Study. Journal of Pain2010;11:994‐1003. ">Choi 2010</a>). Psychosocial stress (e.g. working place and family conflicts) and physical stress (e.g. infections, surgery, accidents) might trigger the onset of chronic widespread pain and fatigue (<a href="./references#CD011804-bbs2-0013" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311:1547‐55. ">Clauw 2014</a>; <a href="./references#CD011804-bbs2-0068" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz2012;26:259‐67. ">Sommer 2012</a>). Depression and post‐traumatic stress disorder worsen fibromyalgia symptoms (<a href="./references#CD011804-bbs2-0029" title="HäuserW , GalekA , Erbslöh‐MöllerB , KöllnerV , Kühn‐BeckerH , LanghorstJ , et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain2013;154:1216‐23. ">Häuser 2013a</a>; <a href="./references#CD011804-bbs2-0037" title="LangeM , PetermannF . Influence of depression on fibromyalgia: a systematic review. Schmerz2010;24:326‐33. ">Lange 2010</a>). </p> <p>Several factors are associated with the pathophysiology (functional changes associated with or resulting from disease) of fibromyalgia, but the relationship is unclear. The functional changes include alteration of sensory processing in the brain, reduced reactivity of the hypothalamus‐pituitary‐adrenal axis to stress, increased pro‐inflammatory and reduced anti‐inflammatory cytokine profiles (produced by cells involved in inflammation), disturbances in neurotransmitters such as dopamine and serotonin, and small fibre pathology (<a href="./references#CD011804-bbs2-0062" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154:2310‐6. ">Oaklander 2013</a>; <a href="./references#CD011804-bbs2-0068" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz2012;26:259‐67. ">Sommer 2012</a>; <a href="./references#CD011804-bbs2-0083" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel‐SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136:e247. ">Üçeyler 2013a</a>). Prolonged exposure to stress, as outlined above, may contribute to these functional changes in predisposed individuals (<a href="./references#CD011804-bbs2-0010" title="BradleyLA . Pathophysiology of fibromyalgia. American Journal Medicine2009;122:S22‐30. ">Bradley 2009</a>). </p> <p>Fibromyalgia is common. Numerous studies have investigated prevalence in different settings and countries. A review gives a global mean prevalence of 2.7% (range 0.4% to 9.3%), and a mean in the Americas of 3.1%, in Europe of 2.5% and in Asia of 1.7%. Fibromyalgia is more common in women, with a female to male ratio of 3:1 (4.2%:1.4%) (<a href="./references#CD011804-bbs2-0064" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5] ">Queiroz 2013</a>). The change in diagnostic criteria does not appear to have significantly affected estimates of prevalence (<a href="./references#CD011804-bbs2-0079" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care &amp; Research2013;645(5):777‐85. [DOI: 10.1002/acr.21931] ">Wolfe 2013</a>). Estimates of prevalence in specific populations vary greatly, but have been reported to be as high as 9% in female textile workers in Turkey and 10% in metalworkers in Brazil (59% in those with repetitive strain injury; <a href="./references#CD011804-bbs2-0064" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5] ">Queiroz 2013</a>). </p> <p>Fibromyalgia pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. A multidisciplinary approach is recommended by recent evidence‐based guidelines, with pharmacological treatment being combined with physical or cognitive training, or both. Interventions aim to reduce the key symptoms of fibromyalgia (pain, sleep problems, fatigue) and the associated symptoms (e.g. depression, disability) and to improve daily functioning (<a href="./references#CD011804-bbs2-0018" title="EichW , HäuserW , ArnoldB , BernardyK , BrückleW , EidmannU , et al. Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz2012;26:268‐75. ">Eich 2012</a>; <a href="./references#CD011804-bbs2-0020" title="FitzcharlesMA , Ste‐MariePA , GoldenbergDL , PereiraJX , AbbeyS , ChoinièreM , et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research Management2013;18:119‐26. ">Fitzcharles 2013</a>). Conventional analgesics are usually not effective. Treatment is often offered with antidepressants like serotonin and noradrenaline reuptake inhibitors (<a href="./references#CD011804-bbs2-0030" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292] ">Häuser 2013b</a>; <a href="./references#CD011804-bbs2-0040" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD007115] ">Lunn 2014</a>), tricyclic agents such as amitriptyline (<a href="./references#CD011804-bbs2-0057" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD011824] ">Moore 2015</a>), or anticonvulsants like gabapentin or pregabalin (<a href="./references#CD011804-bbs2-0050" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011a</a>; <a href="./references#CD011804-bbs2-0084" title="ÜçeylerN , SommerC , WalittB , HäuserW . Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010782] ">Üçeyler 2013b</a>; <a href="./references#CD011804-bbs2-0075" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013</a>). The proportion of people who achieve worthwhile pain relief (typically at least a 50% reduction in pain intensity) is small (<a href="./references#CD011804-bbs2-0054" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>), and generally only 10% to 25% more than with placebo, with numbers needed to treat to benefit (NNTB) between 9.8 and 14 (<a href="./references#CD011804-bbs2-0034" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339. [DOI: 10.1136/bmj.f7339] ">Kalso 2013</a>; <a href="./references#CD011804-bbs2-0075" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013</a>). Those who do experience good levels of pain relief by pregabalin, however, also benefit from substantial reductions in other symptoms, such as fatigue, function, sleep, depression, anxiety and ability to work, with significant improvement in quality of life (<a href="./references#CD011804-bbs2-0048" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010c</a>; <a href="./references#CD011804-bbs2-0071" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471‐2474‐12‐125] ">Straube 2011</a>). Fibromyalgia is not particularly different from other chronic pain for the small proportion of trial participants who have a good response to analgesic treatment (<a href="./references#CD011804-bbs2-0055" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). </p> </section> <section id="CD011804-sec-0025"> <h3 class="title" id="CD011804-sec-0025">Description of the intervention</h3> <p>There is a need for additional pharmacological therapeutic options for the treatment of fibromyalgia symptoms. Antipsychotics (also known as neuroleptics) are a class of psychiatric medication primarily used to manage psychosis symptoms such as hallucinations or disordered thought, in particular in schizophrenia and bipolar disorder. Antipsychotics are increasingly used in the management of non‐psychotic mental disorders such as anxiety disorders (<a href="./references#CD011804-bbs2-0007" title="AmmarG , NajaWJ , PelissoloA . Treatment‐resistant anxiety disorders: a literature review of drug therapy strategies. Encephale2015;41(3):260‐5. ">Ammar 2015</a>), depressive disorders (<a href="./references#CD011804-bbs2-0017" title="EdwardsSJ , HamiltonV , NhereraL , TrevorN . Lithium or an atypical antipsychotic drug in the management of treatment‐resistant depression: a systematic review and economic evaluation. Health Technology Assessment2013;17:1‐190. ">Edwards 2013</a>), post‐traumatic stress disorder (<a href="./references#CD011804-bbs2-0074" title="WangHR , WooYS , BahkWM . Atypical antipsychotics in the treatment of posttraumatic stress disorder. Clinical Neuropharmacology2013;36:216‐22. ">Wang 2013</a>), and somatoform disorders (<a href="./references#CD011804-bbs2-0035" title="KleinstäuberM , WitthöftM , SteffanowskiA , vanMarwijkH , HillerW , LambertMJ . Pharmacological interventions for somatoform disorders in adults. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD010628.pub2] ">Kleinstäuber 2014</a>). These non‐psychotic mental disorders are frequently associated with fibromyalgia (<a href="./references#CD011804-bbs2-0023" title="GalekA , Erbslöh‐MöllerB , KöllnerV , Kühn‐BeckerH , LanghorstJ . Mental disorders in patients with fibromyalgia syndrome: screening in centres of different medical specialties. Schmerz2013;27:296‐304. ">Galek 2013</a>). For these reasons, antipsychotics have been used to treat fibromyalgia symptoms (<a href="./references#CD011804-bbs2-0066" title="Rico‐VillademorosF , CalandreEP , SlimM . Current status of atypical antipsychotics for the treatment of fibromyalgia. Drugs Today2014;50:435‐44. ">Rico‐Villademoros 2014</a>). The role of antipsychotics as adjuvant analgesics for chronic pain is a subject of longstanding controversy in terms of their efficacy and safety (<a href="./references#CD011804-bbs2-0067" title="SeidelS , AignerM , OssegeM , PernickaE , WildnerB , SychaT . Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3] ">Seidel 2013</a>). </p> </section> <section id="CD011804-sec-0026"> <h3 class="title" id="CD011804-sec-0026">How the intervention might work</h3> <p>In addition to blocking dopamine (D2) receptors, which accounts for their efficacy in treating psychoses, second‐generation antipsychotics (so‐called atypical antipsychotics) can act upon different adrenergic, acetylcholine, catecholamines, histamine and serotonin receptors in the brain. First‐ and second‐generation antipsychotics have shown analgesic properties both in an experimental setting and in humans, although most of the available evidence for the treatment of human pain concerns older antipsychotics and involves clinical trials performed several decades ago (<a href="./references#CD011804-bbs2-0011" title="CalandreEP , Rico‐VillademorosF . The role of antipsychotics in the management of fibromyalgia. CNS Drugs2012;26:135‐53. ">Calandre 2012</a>). In addition, several second‐generation antipsychotics, risperidone, olanzapine and quetiapine, have shown efficacy in the treatment of some anxiety disorders (<a href="./references#CD011804-bbs2-0007" title="AmmarG , NajaWJ , PelissoloA . Treatment‐resistant anxiety disorders: a literature review of drug therapy strategies. Encephale2015;41(3):260‐5. ">Ammar 2015</a>). Some second‐generation antipsychotics, mainly quetiapine, aripiprazole and amisulpiride, have demonstrated antidepressant activity, with quetiapine approved for the treatment of bipolar depression and refractory major depression, and aripiprazole approved as an adjunctive treatment for major depressive disorder (<a href="./references#CD011804-bbs2-0017" title="EdwardsSJ , HamiltonV , NhereraL , TrevorN . Lithium or an atypical antipsychotic drug in the management of treatment‐resistant depression: a systematic review and economic evaluation. Health Technology Assessment2013;17:1‐190. ">Edwards 2013</a>). Finally, several old and new antipsychotics, including promethazine, levomepromazine, olanzapine, quetiapine and ziprasidone, have been shown to improve sleep parameters in healthy participants. Each of these properties suggests that antipsychotics could represent a new potential alternative for the treatment of some key fibromyalgia symptoms, such as pain and sleep problems, and of some minor symptoms, such as anxiety and depression (<a href="./references#CD011804-bbs2-0011" title="CalandreEP , Rico‐VillademorosF . The role of antipsychotics in the management of fibromyalgia. CNS Drugs2012;26:135‐53. ">Calandre 2012</a>). As second‐generation antipsychotics may have both fewer extrapyramidal side effects and additional benefits (<a href="./references#CD011804-bbs2-0067" title="SeidelS , AignerM , OssegeM , PernickaE , WildnerB , SychaT . Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3] ">Seidel 2013</a>), such a new drug treatment may be useful for fibromyalgia treatment. </p> </section> <section id="CD011804-sec-0027"> <h3 class="title" id="CD011804-sec-0027">Why it is important to do this review</h3> <p>The serotonin and norepinephrine reuptake inhibitors duloxetine and milnacipran and the anticonvulsant pregabalin have been approved by the US Food and Drug Administration (FDA), but not by the European Medical Agencies (EMA), for the management of for fibromyalgia (<a href="./references#CD011804-bbs2-0030" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292] ">Häuser 2013b</a>; <a href="./references#CD011804-bbs2-0084" title="ÜçeylerN , SommerC , WalittB , HäuserW . Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010782] ">Üçeyler 2013b</a>). Antipsychotics have been approved as adjunctive treatment for major depression in most countries worldwide. The use of antipsychotics in fibromyalgia has been reported in case series and uncontrolled trials (<a href="./references#CD011804-bbs2-0066" title="Rico‐VillademorosF , CalandreEP , SlimM . Current status of atypical antipsychotics for the treatment of fibromyalgia. Drugs Today2014;50:435‐44. ">Rico‐Villademoros 2014</a>). Therefore, there is a need to evaluate the efficacy, tolerability and safety of antipsychotics in fibromyalgia in order to assist fibromyalgia patients and doctors in shared decision making on additional pharmacological treatment options. </p> <p>The standards used to assess evidence in chronic pain trials have changed substantially, with particular attention being paid to trial duration, withdrawals and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using average pain scores, or average change in pain scores, to the number of patients who have a marked decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of 8 to 12 weeks or longer. Pain intensity reduction of 50% or more has been shown to correlate with improvements in comorbid symptoms, function and quality of life. These standards are set by the Cochrane Pain, Palliative and Supportive Care Review Group (<a href="./references#CD011804-bbs2-0014" title="CochranePain , Palliative &amp; Supportive Care Review Group. PaPaS Author and Referee Guidance. Authoring or assessing a Cochrane Protocol, Review, or Review Update for the PaPaS Review Group. Document version 1. September 2011. http://papas.cochrane.org/papas‐documents (accessed 22 August 2015). ">Cochrane PaPaS Group 2011</a>). </p> <p>This Cochrane review assesses the evidence in ways that make both statistical and clinical sense, and uses developing criteria for what constitutes reliable evidence in chronic pain. This sets high standards and marks a change from how reviews were done previously (<a href="./references#CD011804-bbs2-0046" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011804-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011804-sec-0028"></div> <p>To assess the efficacy, tolerability and safety of antipsychotics in fibromyalgia in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011804-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011804-sec-0029"></div> <section id="CD011804-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011804-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included studies if they were randomised or quasi‐randomised controlled trials (RCTs) following four weeks of treatment or longer. We enrolled studies with a parallel, cross‐over and enriched enrollment randomised withdrawal design. Trials should have at least 10 participants per treatment arm. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non‐randomised, studies of experimental pain, case reports and clinical observations. </p> </section> <section id="CD011804-sec-0032"> <h4 class="title">Types of participants</h4> <p>Studies included adult participants aged 18 years and above, diagnosed with fibromyalgia using the ACR 1990 classification criteria (<a href="./references#CD011804-bbs2-0076" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160‐72. ">Wolfe 1990</a>), the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD011804-bbs2-0077" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care &amp; Research2010;62:600‐10. ">Wolfe 2010</a>), or the modified ACR 2010 preliminary diagnostic criteria (research criteria) ( <a href="./references#CD011804-bbs2-0078" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology2011;38:1113‐22. ">Wolfe 2011</a>). </p> </section> <section id="CD011804-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Antipsychotics at any dose, by any route, administered for the relief of fibromyalgia symptoms and compared to placebo or any active comparator. </p> </section> <section id="CD011804-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale or visual analogue scale) for pain intensity or pain relief, or both. We were particularly interested in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD011804-bbs2-0016" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These dichotomous outcomes should be used where pain responses do not follow a normal (Gaussian) distribution. Patients with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (<a href="./references#CD011804-bbs2-0054" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>; <a href="./references#CD011804-bbs2-0061" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x] ">O'Brien 2010</a>). </p> <p>We included a 'Summary of findings' table as per the guidelines given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011804-bbs2-0027" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The 'Summary of findings' table includes the primary outcomes as outlined below. </p> <section id="CD011804-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011804-list-0001"> <li> <p>Participant‐reported pain relief of 50% or greater</p> </li> <li> <p>PGIC much or very much improved</p> </li> <li> <p>Withdrawal due to adverse events (tolerability)</p> </li> <li> <p>Serious adverse events (safety)</p> </li> </ul> </p> </section> <section id="CD011804-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011804-list-0002"> <li> <p>Participant‐reported pain relief of 30% or greater</p> </li> <li> <p>Sleep problems (continuous variable)</p> </li> <li> <p>Depression (continuous variable)</p> </li> <li> <p>Anxiety (continuous variable)</p> </li> <li> <p>Fatigue (continuous variable)</p> </li> <li> <p>Participant‐reported improvement of health‐related quality of life in the Fibromyalgia Impact Questionnaire (FIQ) (<a href="./references#CD011804-bbs2-0009" title="BennettRM , BushmakinAG , CappelleriJC , ZlatevaG , SadoskyAB . Minimal clinically important difference in the fibromyalgia impact questionnaire. Journal of Rheumatology2009;36:1304‐11. ">Bennett 2009</a>) of 14% or greater </p> </li> <li> <p>Withdrawals due to lack of efficacy</p> </li> <li> <p>Participants experiencing any adverse event</p> </li> <li> <p>Other specific adverse events such as somnolence, dizziness and weight gain</p> </li> </ul> </p> </section> </section> </section> <section id="CD011804-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011804-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases without language restrictions:</p> <p> <ul id="CD011804-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 4);</p> </li> <li> <p>MEDLINE via Ovid (1946 to 20 May, 2016);</p> </li> <li> <p>EMBASE via Ovid (1974 to 20 May, 2016).</p> </li> </ul> </p> <p>See <a href="./appendices#CD011804-sec-0125">Appendix 2</a> for the MEDLINE search strategy, <a href="./appendices#CD011804-sec-0126">Appendix 3</a> for the CENTRAL search strategy and <a href="./appendices#CD011804-sec-0127">Appendix 4</a> for the EMBASE search strategy. </p> </section> <section id="CD011804-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We screened the bibliographies of identified randomised trials and relevant review articles for additional information. We also contacted the authors of RCTs with antipsychotics in fibromyalgia and known experts in the field for potential unpublished trials and data. </p> <p>For ongoing studies, we searched clinical trial databases including ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). We contacted investigators or study sponsors for missing data. </p> </section> </section> <section id="CD011804-sec-0040"> <h3 class="title" id="CD011804-sec-0040">Data collection and analysis</h3> <section id="CD011804-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that did not satisfy the inclusion criteria, and obtained full copies of the remaining studies; two review authors (WH, BW) made the decisions. Both of them read these studies independently and reached agreement by discussion. We did not anonymise the studies in any way before assessment. We created a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow chart to illustrate our study selection process. </p> </section> <section id="CD011804-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WH, NÜ) independently extracted data using a pre‐standardised data extraction form and checked for agreement before entering data into Cochrane's statistical software, <a href="./references#CD011804-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>. We included information about the study setting, demographic and clinical variables of the patients, number of participants treated, drug and dosing regimen, co‐medication, study design (placebo or active control), study duration and follow‐up, outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, or serious adverse event). </p> </section> <section id="CD011804-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (WH, NÜ) independently assessed risk of bias in included studies using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011804-bbs2-0027" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), with any disagreements resolved by discussion. </p> <p>We assessed the following risks of bias for each study.</p> <p> <ul id="CD011804-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (i.e. any truly random process, for example random number table; computer random number generator); unclear risk of bias (when the method used to generate the sequence is not clearly stated); high risk of bias (e.g. allocation is generated in terms of odd or even numbers in the date of birth, date of hospital admission or hospital record number, as well as in the case of allocation by judgement of the physician, the patient’s wishes, results of a laboratory test or availability of the intervention). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (for example, telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when the method is not clearly stated); high risk of bias (systematic selection bias if participants and investigators could possibly foresee allocations, for example due to the use of an openly available treatment plan (e.g. a list with randomly generated numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed, non‐opaque or not sequentially numbered). </p> </li> <li> <p>Blinding of participants and personnel/treatment providers (systematic performance bias). We assessed the methods used to blind participants and personnel/treatment providers from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, for example, identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved); high risk (blinding of participants was not ensured, e.g. tablets different in form or taste). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that outcome assessor was not involved in treatment); unclear risk of bias (study states that the assessor was blinded but does not provide an adequate description of how it was achieved); high risk: data analysis was conduced by the investigators. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study and/or used 'baseline observation carried forward' analysis); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes in the study protocol were reported in the publications of the study. There is low risk of reporting bias if the study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way, or if the study protocol is not available but it is clear that the published reports contain all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon). There is a high risk of reporting bias if not all of the study’s prespecified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (for example subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study. </p> </li> <li> <p>Group similarity at baseline (selection bias). We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. There is low risk of bias if groups are similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. There is an unclear risk of bias if baseline for demographic factors, value of main outcome measure(s), and important prognostic factors are not or incompletely reported. There is high risk of bias if groups are not similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> <p>We defined studies with 0 to 2 unclear or high risks of bias to be high quality studies, with 3 to 5 unclear or high risks of bias to be moderate quality studies, and with 6 to 8 unclear or high risks of bias to be low quality studies (<a href="./references#CD011804-bbs2-0033" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , et al. Methodology of the development of the updated LONTS guidelines for long‐term administration of opioids in noncancer pain. Schmerz2015;29:8‐34. ">Häuser 2015b</a>). </p> </section> <section id="CD011804-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated numbers needed to treat for an additional benefit (NNTB) as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD011804-bbs2-0041" title="McQuayH , MooreR . An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 978‐0192630483] ">McQuay 1998</a>). For unwanted effects, the NNTB becomes the number needed to treat for an additional harm (NNTH) and is calculated in the same manner. For dichotomous data we calculated risk differences (RRD) (method inverse variance) with 95% confidence intervals (CIs) using a random‐effects model because we found clinical heterogeneity (different numbers of patients with major depressive disorder in both placebo‐controlled studies) (<a href="#CD011804-sec-0047">Assessment of heterogeneity</a>). We set the threshold for a clinically relevant benefit or a clinically relevant harm for categorical variables as a NNTB or NNTH of less than 10 (<a href="./references#CD011804-bbs2-0044" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). For continuous data we calculated standardised mean differences (SMDs) with 95% confidence intervals (CIs) using a random‐effects model because we found clinical heterogeneity (different numbers of patients with major depressive disorder in both placebo‐controlled studies). We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g of 0.2 = small, 0.5 = medium and 0.8 = large (<a href="./references#CD011804-bbs2-0015" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates, 1998. ">Cohen 1988</a>). We labelled g &lt; 0.2 to be a 'not substantial' effect size. We assumed a minimally important difference if Hedges' g was ≥ 0.2 (<a href="./references#CD011804-bbs2-0019" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Research2014;23:1‐4. ">Fayers 2014</a>). We calculated the numbers needed to treat for an additional outcome of benefit (NNTB) for continuous variables (sleep problems, depression) using the Wells calculator software available at the Cochrane Musculoskeletal Group editorial office, which estimates the proportion of patients who will benefit from treatment from SMDs. The estimation of responders is nearly independent from the minimally important difference (MID) (<a href="./references#CD011804-bbs2-0060" title="NormanGR , SridharFG , GuyattGH , WalterSD . Relation of distribution‐ and anchor‐based approaches in interpretation of changes in health‐related quality of life. Medical Care2001;39:1039‐47. ">Norman 2001</a>). We used a minimal clinically important difference of 15% for the calculation of NNTB from SMDs for all continuous outcomes. </p> </section> <section id="CD011804-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. We included one study with a cross‐over design because separated data from the two periods were reported. </p> </section> <section id="CD011804-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Where means or standard deviations (SDs) were missing, we attempted to obtain these data through contacting trial authors. Where SDs were not available from trial authors, we calculated them from t‐values, CIs or standard errors, where reported in articles (<a href="./references#CD011804-bbs2-0027" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Where 30% and 50% pain reduction rates and 14% FIQ improvement rates were not reported and not provided on request, we calculated them from means and SDs by a validated imputation method (<a href="./references#CD011804-bbs2-0022" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta‐analyses. International Clinical Psychopharmacology2005;20:49‐52. ">Furukawa 2005</a>). </p> </section> <section id="CD011804-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity from combining studies by analysing the inclusion and exclusion criteria of the studies included. We assessed statistical heterogeneity visually (<a href="./references#CD011804-bbs2-0036" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107:224‐33. ">L'Abbé 1987</a>), and with the use of the I<sup>2</sup> statistic. When I<sup>2</sup> was greater than 50%, we considered the possible reasons. </p> </section> <section id="CD011804-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher) (<a href="./references#CD011804-bbs2-0044" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). </p> </section> <section id="CD011804-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model for meta‐analysis because there was significant clinical heterogeneity due to different numbers of patients with major depression in both placebo‐controlled studies. </p> <p>We analysed data in the following three tiers according to outcome and freedom from known sources of bias. </p> <p> <ul id="CD011804-list-0005"> <li> <p>The first tier used data meeting current best standards, where studies report the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of LOCF or other imputation method for drop‐outs, report an intention‐to‐treat (ITT) analysis, last eight or more weeks, have a parallel‐group design, and have at least 200 participants (preferably at least 400) in the comparison (<a href="./references#CD011804-bbs2-0043" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD011804-bbs2-0046" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./references#CD011804-bbs2-0053" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012</a>). We reported these top‐tier results first. </p> </li> <li> <p>The second tier used data from at least 200 participants but where one or more of the above conditions was not met (for example, reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks). </p> </li> <li> <p>The third tier of evidence related to data from fewer than 200 participants, or where there were expected to be significant problems because, for example, of very short duration studies of less than four weeks, where there was major heterogeneity between studies, or where there were shortcomings in allocation concealment, attrition or incomplete outcome data. For this third tier of evidence, no data synthesis is reasonable, and may be misleading, but an indication of beneficial effects might be possible. </p> </li> </ul> </p> <p>We employed the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD011804-bbs2-0025" title="GuyattG , OxmanAD , AklEA . GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011 a</a>) to interpret findings (<a href="./references#CD011804-bbs2-0038" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , et al. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;2:81. ">Langendam 2013</a>), and the GRADE profiler (<a href="./references#CD011804-bbs2-0024" title="BrozekJ , OxmanA , SchünemannH . GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT 2015</a>) allowed us to import data from Review Manager 5.3 (<a href="./references#CD011804-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of the interventions examined and the sum of available data on the outcomes we considered. The GRADE approach defines the quality of the evidence as the extent of confidence in the estimates of treatment benefits and their safety. We made quality ratings separately for each of the 12 outcomes. We downgraded the quality of evidence from 'high quality' by one level for each of the following factors encountered (<a href="./references#CD011804-bbs2-0026" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , et al. GRADE guidelines: 5. Rating the quality of evidence‐‐publication bias. Journal of Clinical Epidemiology2011;64:1277‐82. ">Guyatt 2011 b</a>; <a href="./references#CD011804-bbs2-0033" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , et al. Methodology of the development of the updated LONTS guidelines for long‐term administration of opioids in noncancer pain. Schmerz2015;29:8‐34. ">Häuser 2015b</a>): </p> <p> <ul id="CD011804-list-0006"> <li> <p>Limitations of study design: more than 50% of participants were from low quality studies as defined by the 'Risk of bias' tool. </p> </li> <li> <p>Inconsistency of results: the I² value was above 50%.</p> </li> <li> <p>Indirectness: we assessed whether the question being addressed by the systematic review diverged from the available evidence, in terms of the population in routine clinical care, if exclusion of patients with clinically relevant somatic disease and/or major mental disorders in the included studies resulted in ≥ 50% of the total patient collective of the systematic review coming from studies in which patients with relevant somatic disease and/or major mental disorders were excluded. </p> </li> <li> <p>Imprecision: there was only one trial or where there was more than one trial, the total number was fewer than 400 patients. </p> </li> <li> <p>Publication bias: all studies were initiated and funded by the manufacturer of the drug. </p> </li> </ul> </p> <p>We categorised the quality of evidence as follows (<a href="./references#CD011804-bbs2-0025" title="GuyattG , OxmanAD , AklEA . GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011 a</a>): </p> <p> <ul id="CD011804-list-0007"> <li> <p>High (++++): we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate (+++): we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low (++): our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low (+): we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect; any estimate of effect is very uncertain. </p> </li> </ul> </p> </section> <section id="CD011804-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to pursue subgroup analyses (studies with and without stratifying for comorbid mental disorders; different antipsychotics) if there were at least two studies available. </p> </section> <section id="CD011804-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan to conduct any sensitivity analysis because the evidence base was known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011804-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011804-sec-0052"></div> <section id="CD011804-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD011804-sec-0054"> <h4 class="title">Results of the search</h4> <p>The initial searches identified nine potentially relevant studies in CENTRAL, 38 in MEDLINE and 62 in EMBASE. In addition, we identified one additional study in ClinicalTrials.gov and one study by handsearch. After reading the full reports and after receiving the data from the unpublished study, we included four studies in the review (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>, <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), of which we entered three studies into quantitative analysis (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>) (see <a href="#CD011804-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011804-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011804-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011804-sec-0055"> <h4 class="title">Included studies</h4> <p>We included four studies with 296 participants using quetiapine into qualitative analysis (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), and three studies with 206 participants into quantitative analysis (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>, <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). </p> <p>Study recruitment was reported by three studies and was from multiple sources including general practitioners, rheumatologists, pain units, advertisements in local newspapers, radio or television and local self help organisations (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). Three studies were conducted in tertiary (university) centres (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), and one study was conducted in a regional hospital (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>). The study investigators were affiliated with a department of neuroscience (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>), or with a department of psychiatry (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). One study did not report the affiliation with a department of the authors (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>). All studies were conducted in a single centre. Two studies were conducted in Canada (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), and one study each in Spain (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>) and the USA (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). </p> <p>Studies enrolled adult participants with a mean age ranging between 48 and 50 years. Two studies included only women (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>); the remaining studies included more than 95% women. In all included studies diagnosis of fibromyalgia was established by the ACR 1990 classification criteria (<a href="./references#CD011804-bbs2-0076" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160‐72. ">Wolfe 1990</a>) (see <a href="#CD011804-tbl-0002">Table 1</a>). One study required a diagnosis of comorbid major depression for inclusion (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>). All studies excluded patients with major medical diseases and patients with major mental disorders, except major depression (see <a href="#CD011804-tbl-0002">Table 1</a>). </p> <div class="table" id="CD011804-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Inclusion and exclusion criteria of the studies included in the review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Exclusion criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0008"> <li> <p>Aged 18 to 70 years</p> </li> <li> <p>Fulfilled the 1990 American College of Rheumatology classification criteria</p> </li> <li> <p>Scoring a minimum of 40 on the Fibromyalgia Impact Questionnaire (FIQ) total score and a minimum of 4 on the average pain severity item in the Brief Pain Inventory (BPI) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD011804-list-0009"> <li> <p>Pregnancy, lactation and women of childbearing age not using a valid contraception method </p> </li> <li> <p>Any DSM‐IV‐R Axis I psychiatric disorder other than major depression</p> </li> <li> <p>Major severe depression as evidenced by a Beck Depression Inventory (BDI) score of ≥ 30 </p> </li> <li> <p>Substance and/or alcohol dependence</p> </li> <li> <p>Current clinically relevant cardiovascular, cerebrovascular, renal, hepatic or respiratory disease or any other serious physical illness </p> </li> <li> <p>Uncontrolled diabetes mellitus</p> </li> <li> <p>Unwillingness to discontinue drugs prescribed for fibromyalgia</p> </li> <li> <p>Received quetiapine or amitriptyline within 1 year of randomisation</p> </li> <li> <p>Patients who at randomisation had a change in the FIQ total score of ≥ 20% in relation to the value determined at the screening visit. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0010"> <li> <p>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV)</p> </li> <li> <p>Diagnostic criteria for MDD as confirmed by the Mini‐International Neuropsychiatric Interview score of 22 on the 17‐item Hamilton Depression Rating (HAM‐D) scale and a score of 4 on the Clinical Global Impression–Severity (CGI‐S) scale (i.e. moderately ill) at screening and baseline (study day 0) </p> </li> <li> <p>Diagnosis of fibromyalgia was confirmed by the investigator according to the American College of Rheumatology 1990 criteria </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0011"> <li> <p>DSM‐IV Axis I disorder other than MDD and a chronic pain disorder within 6 months</p> </li> <li> <p>History of an inadequate response to treatment (duration of 6 weeks) with 2 antidepressants during the current depressive episode; diagnosis of a DSM‐IV Axis II disorder with a major impact on the patient's current psychiatric status </p> </li> <li> <p>Use of quetiapine 25 mg/day for insomnia within 7 days of enrollment</p> </li> <li> <p>Female patients of childbearing potential without adequate contraception</p> </li> <li> <p>Pregnant or breastfeeding patients</p> </li> <li> <p>Acute, unstable or significant and untreated medical illness</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0012"> <li> <p>Age 18 to 60, inclusive</p> </li> <li> <p>Females of childbearing potential using a reliable method of contraception AND negative urine pregnancy test </p> </li> <li> <p>Widespread pain present for at least 3 months</p> </li> <li> <p>Widespread encompassing both sides of the body, as well as above and below the waist</p> </li> <li> <p>Pain in at least 11 of 18 tender points as determined by a physician</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0013"> <li> <p>Pregnant or breastfeeding</p> </li> <li> <p>Use of any of the following in the 14 days prior to enrollment: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, saquinavir phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort and glucocorticoids </p> </li> <li> <p>Administration of a depot antipsychotic injection within one dosing interval (for the depot) before enrollment </p> </li> <li> <p>Substance or alcohol dependence at enrollment (except in full or recovery, and except nicotine or caffeine dependence) </p> </li> <li> <p>Abuse of any of the following within 4 weeks of enrollment: opiates, amphetamine, barbiturate, cocaine, cannabis or hallucinogen </p> </li> <li> <p>Medical conditions that would affect study treatment</p> </li> <li> <p>Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by investigator </p> </li> <li> <p>Involvement in the planning and conduct of the study</p> </li> <li> <p>Previous enrollment or randomisation of treatment in the present study</p> </li> <li> <p>Participation in another drug trial within 4 weeks prior to enrollment in this study or longer </p> </li> <li> <p>Admitted to hospital for diabetes mellitus (DM) related illness in past 12 weeks</p> </li> <li> <p>Not under physician's care for DM</p> </li> <li> <p>Physician responsible for DM care has indicated that DM is uncontrolled</p> </li> <li> <p>Physician responsible for DM care has not approved participation in the study</p> </li> <li> <p>Have not been on the same dose of DM medicine and/or diet for the 4 weeks prior to starting the study </p> </li> <li> <p>For thiazolidinediones (glitazones) this period should not be less than 8 weeks</p> </li> <li> <p>Taking insulin and the daily dose on one occasion in the past 4 weeks has been more than 10% above or below the mean dose in the preceding 4 weeks </p> </li> <li> <p>A low white blood cell count</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0014"> <li> <p>Female patients, older than 18 years</p> </li> <li> <p>Meeting the American College of Rheumatology criteria for the diagnosis of fibromyalgia</p> </li> <li> <p>Unsatisfactory response to their previous pharmacological treatment, defined as a score of 4 or greater on the pain severity item of the French version of the Fibromyalgia Impact Questionnaire (FIQ) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0015"> <li> <p>Receiving an antipsychotic</p> </li> <li> <p>Pregnancy or females of childbearing potential without adequate contraception</p> </li> <li> <p>Risk of suicide</p> </li> <li> <p>Any Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I psychiatric disorder other than MDD </p> </li> <li> <p>Any clinically meaningful unstable, renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical illness and diabetes mellitus </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DM: Diabetes mellitus<br/> DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition<br/> FIQ: Fibromyalgia Impact Questionnaire<br/> MDD: Major depressive disorder </p> </div> </div> <p>Three studies used a parallel‐group design (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). One used a cross‐over study design (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). This study provided data from the first phase separately. There was a one‐week washout between phases in the cross‐over study (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). </p> <p>Study duration was eight weeks in one study (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>) and 12 weeks in the remaining studies. </p> <p>The dosage of quetiapine was flexible between 50 and 300 mg/day in two studies (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), flexible between 50 and 300 mg/day in one study (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>) and fixed at 200 mg/day in one study (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). In one study with an active comparator, the dosage of amitriptyline was 10 to 75 mg/day, flexible (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>). </p> </section> <section id="CD011804-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded one study. The reasons for exclusion are listed in the <a href="./references#CD011804-sec-0144" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD011804-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Each study had a high risk of bias in at least one domain (see <a href="#CD011804-fig-0002">Figure 2</a> and <a href="#CD011804-fig-0003">Figure 3</a>). The overall methodological study quality according to the predefined criteria was low in two studies (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>), and moderate in two studies (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). </p> <div class="figure" id="CD011804-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011804-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011804-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011804-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011804-sec-0058"> <h4 class="title">Allocation</h4> <p>All studies were randomised. Random sequence generation and allocation concealment were of low risk in <a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a> and <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>, and unclear in the remaining studies. </p> </section> <section id="CD011804-sec-0059"> <h4 class="title">Blinding</h4> <p>Two studies adequately described the method used to achieve double‐blinding with a low risk of bias (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). One study had a high risk of bias because of its open‐label design (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>). The remaining study had an unclear risk of bias. </p> </section> <section id="CD011804-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies used a last observation forward analysis (unclear risk of bias) (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). One study that had a high risk of bias used a modified intention‐to‐treat‐analysis (at least one measurement after baseline) (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>). </p> </section> <section id="CD011804-sec-0061"> <h4 class="title">Selective reporting</h4> <p>A study protocol was available for each study (low risk of bias).</p> </section> <section id="CD011804-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>The demographic characteristics of the study groups were similar in all studies. Three studies had a high risk of bias due to small sample sizes (fewer than 50 patients per treatment arm) (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>; <a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>), and one study had an unclear risk of bias (50 to 100 patients per treatment arm) (<a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). </p> </section> </section> <section id="CD011804-sec-0063"> <h3 class="title" id="CD011804-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD011804-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD011804-sec-0064"> <h4 class="title">Quetiapine versus placebo</h4> <p>There was second tier evidence available for this comparison. We downgraded the quality of evidence by three levels to a very low rating because of limitations of study design, indirectness (patients with major medical diseases and mental disorders were excluded) and imprecision (fewer than 400 patients analysed). </p> <section id="CD011804-sec-0065"> <h5 class="title">Primary outcomes</h5> <section id="CD011804-sec-0066"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>We entered two studies with 155 participants into the analysis. There was very low quality evidence that there was no statistically significant difference between quetiapine and placebo. Seven of 82 (8.5%) participants with quetiapine and 2/73 (2.7%) participants with placebo reported pain relief of 50% or greater (risk difference (RD) 0.04, 95% confidence interval (CI) ‐0.02 to 0.10; P value = 0.21; I² = 0%) (see <a href="./references#CD011804-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011804-sec-0067"> <h6 class="title">Patient Global Impression of Change (PGIC) much or very much improved</h6> <p>This analysis was not possible because these data were not available.</p> </section> <section id="CD011804-sec-0068"> <h6 class="title">Withdrawal due to adverse events (tolerability)</h6> <p>We entered two studies with 155 participants into the analysis. There was very low quality evidence that there was no statistically significant difference between quetiapine and placebo. Twenty‐four of 82 (29.3%) participants with quetiapine and 13/73 (17.8%) participants with placebo dropped out due to adverse events (RD 0.10, 95% CI ‐0.06 to 0.27; P value = 0.21; I² = 24%) (see <a href="./references#CD011804-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD011804-sec-0069"> <h6 class="title">Serious adverse events (safety)</h6> <p>We entered three studies with 206 participants into the analysis. There was very low quality evidence that there was no statistically significant difference between quetiapine and placebo. One of 86 (1.2%) participants in the quetiapine group (reason: neurocardiogenic syncope as recurrence of pre‐existing condition) and 1/99 (1.0%) participants in the placebo group (reason: pulmonary embolism) reported a serious adverse event (RD ‐0.00, 95% CI ‐0.03 to 0.03; P value = 0.96; I² = 0%) (see <a href="./references#CD011804-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD011804-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD011804-sec-0071"> <h6 class="title">Participant‐reported pain relief of 30% or greater</h6> <p>We entered two studies with 155 participants into the analysis. There was very low quality evidence that there was a statistically significant difference between quetiapine and placebo. Twenty of 82 (24.4%) participants with quetiapine and 8/73 (11.0%) participants with placebo reported pain relief of 30% or greater (RD 0.12, 95% CI 0.00 to 0.23; P value = 0.04; I² = 0%). The number needed to treat for an additional benefit (NNTB) was 8 (95% CI 5 to 100). According to the predefined categories there was a clinically relevant benefit with quetiapine (see <a href="./references#CD011804-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD011804-sec-0072"> <h6 class="title">Sleep problems</h6> <p>We entered two studies with 87 participants into the analysis. There was very low quality evidence that quetiapine was superior to placebo in reducing sleep problems (standardised mean difference (SMD) ‐0.67, 95% CI ‐1.10 to ‐0.23; P value = 0.003; I² = 0%). According to Cohen's categories, there was a medium effect size indicating a minimal clinically important improvement (see <a href="./references#CD011804-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD011804-sec-0073"> <h6 class="title">Depression</h6> <p>We entered three studies with 207 participants into an analysis of depression. There was very low quality evidence that quetiapine was superior to placebo in reducing depressed mood (SMD ‐0.39, 95% CI ‐0.74 to ‐0.04; P value = 0.03; I² = 31%). According to Cohen's categories, there was a small effect size indicating a minimal clinically important improvement (see <a href="./references#CD011804-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD011804-sec-0074"> <h6 class="title">Anxiety</h6> <p>We entered three studies with 206 participants into an analysis of anxiety. There was very low quality evidence that quetiapine was statistically significantly superior to placebo in reducing anxiety (SMD ‐0.40, 95% CI ‐0.69 to ‐0.11; P value = 0.009; I² = 6%). According to Cohen's categories, there was a small effect size indicating a minimal clinically important improvement (see <a href="./references#CD011804-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD011804-sec-0075"> <h6 class="title">Fatigue</h6> <p>We did not conduct the predefined quantitative analysis because the data were not included in the three publications and not provided on request. Participants on quetiapine had a significant improvement (P value = 0.001) on the fatigue subscale of the Fibromyalgia Impact Questionnaire (FIQ), with a mean score reduction of 2.07 ± 2.46 when comparing baseline (8.62 ± 1.38) to week 12 (6.55± 2.56) before cross‐over. Placebo had no effect (P value = 0.12), with a mean score reduction of 0.82 ± 1.83 when comparing baseline (8.86 ± 1.23) to week 12 (8.04 ± 1.75) (<a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). </p> </section> <section id="CD011804-sec-0076"> <h6 class="title">Participant‐reported improvement of health‐related quality of life in the FIQ of 14% or greater </h6> <p>We entered three studies with 206 participants into the analysis. There was very low quality evidence that quetiapine was superior to placebo. Fifty‐three of 107 (49.5%) participants in the quetiapine group and 32/99 (32.3%) participants in the placebo group reported a reduction of 14% or more of the FIQ total score (RD 0.18, 95% CI 0.05 to 0.31; P value = 0.008; I² = 0%). The NNTB was 5 (95% CI 3 to 20). According to the predefined categories there was a clinically relevant benefit from quetiapine (see <a href="./references#CD011804-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD011804-sec-0077"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p>We entered two studies with 155 participants into the analysis. There was very low quality evidence that quetiapine was statistically significantly superior over placebo in reducing drop‐out due to lack of efficacy. Two of 82 (2.4%) in the quetiapine group and 13/73 (17.8%) in the placebo group dropped out due to lack of efficacy (RD ‐0.14, 95% CI ‐0.23 to ‐0.05; P value = 0.003, I² = 0%). The NNTB was 7 (95% CI 4 to 20). According to the predefined categories there was a clinically relevant benefit from quetiapine (see <a href="./references#CD011804-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD011804-sec-0078"> <h6 class="title">Participants experiencing any adverse event</h6> <p>This analysis was not possible because these data were not available.</p> </section> <section id="CD011804-sec-0079"> <h6 class="title">Other specific adverse events</h6> <section id="CD011804-sec-0080"> <p><b>Somnolence</b></p> <p>We entered three studies with 206 participants into an analysis of somnolence as adverse event. There was very low quality evidence that there was no statistically significant difference between quetiapine and placebo. Fifty‐nine of 107 (55.1%) participants in the quetiapine group and 28/93 (30.1%) participants in the placebo group reported somnolence as an adverse event (RD 0.22, 95% CI ‐0.06 to 0.50; P value = 0.12; I² = 86%) (see <a href="./references#CD011804-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD011804-sec-0081"> <p><b>Dizziness</b></p> <p>We entered three studies with 206 participants into the analysis. There was very low quality evidence that there was no statistically significant difference between quetiapine and placebo. Twenty‐seven of 107 (25.2%) participants in the quetiapine group and 22/99 (22.2%) participants in the placebo group reported dizziness as an adverse event (RD 0.05, 95% CI ‐0.05 to 0.14; P value = 0.33; I² = 0%) (see <a href="./references#CD011804-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD011804-sec-0082"> <p><b>Substantial weight gain (&gt; 5 kg)</b></p> <p>We entered two studies with 155 participants into the analysis. There was very low quality evidence that there was a statistically significant difference between quetiapine and placebo. In 7/82 (8.5%) participants with quetiapine and 0/73 (0%) participants with placebo a substantial weight gain was noted (RD 0.08, 95% CI 0.02 to 0.15; P value = 0.01; I² = 0%). The number needed to treat for an additional harm (NNTH) was 12 (95% CI 6 to 50). According to the predefined categories there was no clinically relevant harm from quetiapine (see <a href="./references#CD011804-fig-0015" title="">Analysis 1.12</a>). </p> </section> </section> </section> </section> <section id="CD011804-sec-0083"> <h4 class="title">Antipsychotics versus amitriptyline</h4> <p>There was only third tier evidence available for this comparison. For this third tier evidence, no data synthesis was reasonable and may have been misleading. We therefore did not conduct the planned meta‐analysis and the study results are presented in a narrative fashion. The overall methodological study quality according to the predefined criteria was moderate. We downgraded the quality of evidence by two levels to low because of indirectness (participants with major medical diseases and mental disorders, except major depression, were excluded) and of imprecision (only one study available). The study used a non‐inferiority design with the mean change from baseline to endpoint in the FIQ total score as the primary outcome. The non‐inferiority threshold was established at eight points. The authors failed to demonstrate the non‐inferiority of quetiapine compared to amitriptyline (<a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a>). </p> <section id="CD011804-sec-0084"> <h5 class="title">Primary outcomes</h5> <section id="CD011804-sec-0085"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>There were missing data, therefore this analysis was not possible. There was no statistically significant difference between the two drugs in mean pain reduction (P value = 0.84). </p> </section> <section id="CD011804-sec-0086"> <h6 class="title">PGIC much or very much improved</h6> <p>This analysis was not possible because these data were not available.</p> </section> <section id="CD011804-sec-0087"> <h6 class="title">Withdrawal due to adverse events (tolerability)</h6> <p>There was low quality evidence that more participants dropped out due to adverse events on quetiapine (14/45 (31.1%)) than on amitriptyline (3/45 (6.7%)) (P value = 0.003). </p> </section> <section id="CD011804-sec-0088"> <h6 class="title">Serious adverse events (safety)</h6> <p>No serious adverse events were reported in both groups.</p> </section> </section> <section id="CD011804-sec-0089"> <h5 class="title">Secondary outcomes</h5> <section id="CD011804-sec-0090"> <h6 class="title">Participant‐reported pain relief of 30% or greater</h6> <p>There were missing data, therefore this analysis was not possible.</p> </section> <section id="CD011804-sec-0091"> <h6 class="title">Sleep problems</h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. The mean change from baseline in the quetiapine group was ‐3.9 ± 4.3 and in the amitriptyline group was ‐3.8 ± 4.1 (P value = 0.62). </p> </section> <section id="CD011804-sec-0092"> <h6 class="title">Depression</h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. The mean change from baseline in the quetiapine group was ‐2.1 ± 7.9 and in the amitriptyline group was ‐4.2 ± 7.6 (P value = 0.25) </p> </section> <section id="CD011804-sec-0093"> <h6 class="title">Anxiety</h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. The mean change from baseline in the quetiapine group was ‐5.5 ± 11.2 and in the amitriptyline group was ‐5.9 ± 10.1 (P value = 0.63). </p> </section> <section id="CD011804-sec-0094"> <h6 class="title">Fatigue</h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. The mean change from baseline in the quetiapine group was ‐1.1± 2.3 and in the amitriptyline group was ‐1.3 ± 2.3 (P value = 0.77). </p> </section> <section id="CD011804-sec-0095"> <h6 class="title">Participant‐reported improvement of health‐related quality of life in the FIQ of 14% or greater </h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. Sixteen of 33 (48.5%) participants on quetiapine and 25/43 (58.1%) participants on amitriptyline reported a reduction on the FIQ of 14% or greater (P value = 0.40). </p> </section> <section id="CD011804-sec-0096"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p>There were missing data, therefore the analysis was not possible.</p> </section> <section id="CD011804-sec-0097"> <h6 class="title">Participants experiencing any adverse event</h6> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. Forty‐five of 45 (100%) participants in the quetiapine group and 42/45 (93.3%) participants in the amitriptyline group reported at least one adverse event (P value = 0.08). </p> </section> <section id="CD011804-sec-0098"> <h6 class="title">Other specific adverse events</h6> <section id="CD011804-sec-0099"> <p><b>Somnolence</b></p> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. Fifteen of 45 (33.3%) participants in the quetiapine group and 13/45 (28.9%) participants in the amitriptyline group reported somnolence (P value = 0.21). </p> </section> <section id="CD011804-sec-0100"> <p><b>Dizziness</b></p> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. Seventeen of 45 (37.8%) participants in the quetiapine group and 12/45 (26.7%) participants in the amitriptyline group reported dizziness (P value = 0.26). </p> </section> <section id="CD011804-sec-0101"> <p><b>Weight gain</b></p> <p>There was low quality evidence that there was no statistically significant difference between the two drugs. Weight gain was observed in 7/45 (15.6%) participants in the quetiapine group and in 5/45 (11.1%) participants in the amitriptyline group (P value = 0.54). </p> </section> </section> </section> </section> <section id="CD011804-sec-0102"> <h4 class="title">Assessment of publication bias</h4> <p>One hundred and sixty‐five participants would have to have been included in entirely negative (zero treatment effect) trials to breach the pre‐set level of utility (a NNTB of 10 or more). </p> </section> <section id="CD011804-sec-0103"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The planned subgroup analyses (e.g. studies with and without stratification for comorbid mental disorders) were not possible due to an insufficient number of studies. Most notably, we could not perform subgroup analysis of participants with and without major depression because two studies included participants with and without major depression. Data for an individual patient data analysis were not provided. </p> <p>The heterogeneity of all quantitative analyses was below 50% except for somnolence with an I<sup>2</sup> of 86% . </p> </section> <section id="CD011804-sec-0104"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analysis because we did not identify individual peculiarities of the studies under investigation during the review process that were suitable for sensitivity analyses. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011804-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011804-sec-0105"></div> <section id="CD011804-sec-0106"> <h3 class="title" id="CD011804-sec-0106">Summary of main results</h3> <p>We included a total of four studies with 298 participants. Three randomised controlled studies compared the second‐generation antipsychotic quetiapine to placebo in 208 participants with fibromyalgia, with and without current major depression. Second tier and very low quality evidence indicated that quetiapine was not superior to placebo in inducing substantial (50% or more) pain reduction in some participants. Second tier and very low quality evidence indicated that quetiapine was superior to placebo in inducing moderate (30% or more) pain reduction, in inducing a minimal clinically important difference in health‐related quality of life and in reducing average scores for sleep problems, depressed mood and anxiety to a clinically relevant degree in some participants. Participants taking quetiapine did not drop out due to adverse events nor report more serious adverse events than did participants taking placebo. Somnolence and substantial weight gain were clinically relevant side effects of quetiapine. </p> <p>The review also found one randomised controlled study with a non‐inferiority design, which compared the antipsychotic quetiapine with the tricyclic antidepressant amitriptyline in 90 participants with fibromyalgia, with and without current major depression. Third tier and low quality evidence indicated that there was no difference between the two drugs in the outcomes of efficacy (reduction of mean scores for pain, health‐related quality of life, sleep problems, fatigue, depression, anxiety) and safety. More participants dropped out due to adverse events in the quetiapine group than in the amitriptyline group. </p> <p>We did not find randomised controlled trials with other antipsychotics than quetiapine.</p> </section> <section id="CD011804-sec-0107"> <h3 class="title" id="CD011804-sec-0107">Overall completeness and applicability of evidence</h3> <p>The overall completeness and applicability of the evidence were poor. The usefulness of the available evidence is limited because reporting quality was poor by current standards (<a href="./references#CD011804-bbs2-0046" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). The authors of two studies did not provide additional information on request (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>). The applicability of the evidence to routine clinical care is limited because patients with mental disorders other than major depression and with major medical diseases were excluded by all studies. </p> </section> <section id="CD011804-sec-0108"> <h3 class="title" id="CD011804-sec-0108">Quality of the evidence</h3> <p>We found the evidence for most outcomes to be of very low quality, primarily due to risks of bias such as limitations of study design and imprecise results because of small study sample sizes. </p> </section> <section id="CD011804-sec-0109"> <h3 class="title" id="CD011804-sec-0109">Potential biases in the review process</h3> <p>The absence of publication bias (unpublished trials showing no benefit of antipsychotics over placebo) can never be proved. We carried out a broad search for studies and feel it is unlikely that significant amounts of relevant data remain unknown to us. </p> </section> <section id="CD011804-sec-0110"> <h3 class="title" id="CD011804-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in line with those of a narrative review on the role of antipsychotics in fibromyalgia, which concluded that very low quality evidence has demonstrated the superiority of quetiapine over placebo in treating comorbid major depression and sleep disturbance, and that quetiapine failed to demonstrate non‐inferiority to amitriptyline in terms of improving overall symptomatology (<a href="./references#CD011804-bbs2-0066" title="Rico‐VillademorosF , CalandreEP , SlimM . Current status of atypical antipsychotics for the treatment of fibromyalgia. Drugs Today2014;50:435‐44. ">Rico‐Villademoros 2014</a>). </p> <p>Our conclusions are also in line with those of a Cochrane review on antipsychotics in acute and chronic pain, which found that antipsychotics might be considered as an add‐on therapy in the treatment of some painful conditions, for example fibromyalgia (<a href="./references#CD011804-bbs2-0067" title="SeidelS , AignerM , OssegeM , PernickaE , WildnerB , SychaT . Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3] ">Seidel 2013</a>). Nevertheless, side effects have to be considered before using antipsychotics (<a href="./references#CD011804-bbs2-0067" title="SeidelS , AignerM , OssegeM , PernickaE , WildnerB , SychaT . Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3] ">Seidel 2013</a>). The use of atypical antipsychotics can be associated with substantial weight gain and resulting metabolic syndrome (<a href="./references#CD011804-bbs2-0073" title="VentriglioA , GentileA , StellaE , BellomoA . Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Frontiers in Neuroscience2015;9:297. ">Ventriglio 2015</a>). Chronic pain syndromes such as fibromyalgia and obesity are significant comorbidities, which adversely impact each other (<a href="./references#CD011804-bbs2-0063" title="OkifujiA , HareBD . The association between chronic pain and obesity. Journal Pain Research2015;14:399‐408. ">Okifuji 2015</a>). The use of atypical antipsychotics in obese patients with fibromyalgia should therefore be carefully considered. </p> <p>Quetiapine reduced anxiety and depression in all studies included into analysis (<a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a>; <a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a>; <a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a>). A systematic review with network meta‐analysis found that all standard‐dose atypical antipsychotics for the adjunctive treatment of therapy‐resistant depression are efficacious in reducing depressive symptoms. However, atypical antipsychotics should be prescribed with caution due to abundant evidence of side effects (<a href="./references#CD011804-bbs2-0082" title="ZhouX , KeitnerGI , QinB , RavindranAV , BauerM , DelGiovaneC , et al. Atypical antipsychotic augmentation for treatment‐resistant depression: a systematic review and network meta‐analysis. International Journal of Psychopharmacology2015;18(11):pyv060. ">Zhou 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011804-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011804-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011804-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011804-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 1 &gt;= 50% pain relief." data-id="CD011804-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 1 &gt;= 50% pain relief.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 2 Drop‐out due to adverse events." data-id="CD011804-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 2 Drop‐out due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 3 Serious adverse events." data-id="CD011804-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 4 &gt;= 30% pain reduction." data-id="CD011804-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 4 &gt;= 30% pain reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 5 Sleep problems." data-id="CD011804-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 5 Sleep problems.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 6 Depression." data-id="CD011804-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 6 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 7 Anxiety." data-id="CD011804-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 7 Anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 8 &gt;= 14% improvement of health‐related quality of life." data-id="CD011804-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 8 &gt;= 14% improvement of health‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 9 Drop‐out due to lack of efficacy." data-id="CD011804-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 9 Drop‐out due to lack of efficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 10 Somnolence." data-id="CD011804-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 10 Somnolence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 11 Dizziness." data-id="CD011804-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 11 Dizziness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011804-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/urn:x-wiley:14651858:media:CD011804:CD011804-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_t/tCD011804-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antipsychotics versus placebo, Outcome 12 Substantial weight gain." data-id="CD011804-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Antipsychotics versus placebo, Outcome 12 Substantial weight gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/media/CDSR/CD011804/image_n/nCD011804-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011804-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antipsychotics compared with placebo for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with fibromyalgia </p> <p><b>Settings:</b> research centres </p> <p><b>Intervention:</b> quetiapine 50 to 300 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD, risk difference and NNTB/NNTH<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 50 % pain relief</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB not calculated because of lack of statistical significance</b> </p> <p><b>RD 0.04</b> <br/> (‐0.02 to 0.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change much or very much improved</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b>No data</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sleep problems</b> </p> <p>(Scale 0 to 21; higher scores indicate more sleep problems) <sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sleep problems in the intervention groups was<br/> <b>0.67 standard deviations lower</b> <br/> (1.1 to 0.23 lower) </p> <p><b>NNTB</b> 4 (2 to 12) </p> <p><b>SMD</b> ‐0.67 (‐1.1 to ‐0.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>(Scale 0 to 50) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the intervention groups was<br/> <b>0.39 standard deviations lower</b> <br/> (0.74 to 0.04 lower) </p> <p><b>NNTB</b> 6 (3 to 53) </p> <p><b>SMD</b> ‐0.39 (‐0.74 to ‐0.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH not calculated because of lack of statistical significance</b> </p> <p><b>RD 0.10</b> <br/> (‐0.06 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH not calculated because of lack of statistical significance</b> </p> <p><b>RR ‐</b>0.00 (‐0.03 to 0.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Substantial weight gain</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH 12 (95% CI 0.02 to 0.15)</b> </p> <p><b>RD 0.08</b> <br/> (0.02 to 0.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> <p><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the risk ratio of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional benefit; <b>NNTH</b> : number needed to treat for an additional harm; <b>RD:</b> risk difference; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations of study design (&gt; 50% participants in low quality studies). </p> <p><sup>2</sup>Imprecision: fewer than 400 participants. </p> <p><sup>3</sup>Indirectness: patients with major medical diseases and mental disorders, except major depression, were excluded. </p> <p><sup>4</sup>Potvin 2012: baseline score for sleep problems in control group: 12.8 (SD 4.3). Higher scores indicate more sleep problems. </p> <p><sup>5</sup>McIntyre 2014: baseline score for depression 24.6 (SD 11.5). Higher scores indicate more depression. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011804-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Inclusion and exclusion criteria of the studies included in the review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Exclusion criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0001" title="CalandreEP , Rico‐VillademorosF , GalánJ , Molina‐BareaR , VilchezJS , et al. Quetiapine extended‐release (Seroquel‐XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16‐week, randomized, flexible‐dose, open‐label trial. Psychopharmacology2014;231:2525‐31. ">Calandre 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0008"> <li> <p>Aged 18 to 70 years</p> </li> <li> <p>Fulfilled the 1990 American College of Rheumatology classification criteria</p> </li> <li> <p>Scoring a minimum of 40 on the Fibromyalgia Impact Questionnaire (FIQ) total score and a minimum of 4 on the average pain severity item in the Brief Pain Inventory (BPI) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD011804-list-0009"> <li> <p>Pregnancy, lactation and women of childbearing age not using a valid contraception method </p> </li> <li> <p>Any DSM‐IV‐R Axis I psychiatric disorder other than major depression</p> </li> <li> <p>Major severe depression as evidenced by a Beck Depression Inventory (BDI) score of ≥ 30 </p> </li> <li> <p>Substance and/or alcohol dependence</p> </li> <li> <p>Current clinically relevant cardiovascular, cerebrovascular, renal, hepatic or respiratory disease or any other serious physical illness </p> </li> <li> <p>Uncontrolled diabetes mellitus</p> </li> <li> <p>Unwillingness to discontinue drugs prescribed for fibromyalgia</p> </li> <li> <p>Received quetiapine or amitriptyline within 1 year of randomisation</p> </li> <li> <p>Patients who at randomisation had a change in the FIQ total score of ≥ 20% in relation to the value determined at the screening visit. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0002" title="McIntyreA , PaisleyD , KouassiE , GendronA . Quetiapine fumarate extended‐release for the treatment of major depression with comorbid fibromyalgia syndrome: a double‐blind, randomized, placebo‐controlled study. Arthritis and Rheumatism2014;66:455‐61. ">McIntyre 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0010"> <li> <p>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV)</p> </li> <li> <p>Diagnostic criteria for MDD as confirmed by the Mini‐International Neuropsychiatric Interview score of 22 on the 17‐item Hamilton Depression Rating (HAM‐D) scale and a score of 4 on the Clinical Global Impression–Severity (CGI‐S) scale (i.e. moderately ill) at screening and baseline (study day 0) </p> </li> <li> <p>Diagnosis of fibromyalgia was confirmed by the investigator according to the American College of Rheumatology 1990 criteria </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0011"> <li> <p>DSM‐IV Axis I disorder other than MDD and a chronic pain disorder within 6 months</p> </li> <li> <p>History of an inadequate response to treatment (duration of 6 weeks) with 2 antidepressants during the current depressive episode; diagnosis of a DSM‐IV Axis II disorder with a major impact on the patient's current psychiatric status </p> </li> <li> <p>Use of quetiapine 25 mg/day for insomnia within 7 days of enrollment</p> </li> <li> <p>Female patients of childbearing potential without adequate contraception</p> </li> <li> <p>Pregnant or breastfeeding patients</p> </li> <li> <p>Acute, unstable or significant and untreated medical illness</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0003" title="NCT01458964 . Quetiapine compared with placebo in the management of fibromyalgia. https://clinicaltrials.gov/ct2/show/NCT01458964?term=quetiapine+and+fibromyalgia&amp;rank=3 8 July 2014; data provided on request. ">NCT01458964</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0012"> <li> <p>Age 18 to 60, inclusive</p> </li> <li> <p>Females of childbearing potential using a reliable method of contraception AND negative urine pregnancy test </p> </li> <li> <p>Widespread pain present for at least 3 months</p> </li> <li> <p>Widespread encompassing both sides of the body, as well as above and below the waist</p> </li> <li> <p>Pain in at least 11 of 18 tender points as determined by a physician</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0013"> <li> <p>Pregnant or breastfeeding</p> </li> <li> <p>Use of any of the following in the 14 days prior to enrollment: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, saquinavir phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort and glucocorticoids </p> </li> <li> <p>Administration of a depot antipsychotic injection within one dosing interval (for the depot) before enrollment </p> </li> <li> <p>Substance or alcohol dependence at enrollment (except in full or recovery, and except nicotine or caffeine dependence) </p> </li> <li> <p>Abuse of any of the following within 4 weeks of enrollment: opiates, amphetamine, barbiturate, cocaine, cannabis or hallucinogen </p> </li> <li> <p>Medical conditions that would affect study treatment</p> </li> <li> <p>Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by investigator </p> </li> <li> <p>Involvement in the planning and conduct of the study</p> </li> <li> <p>Previous enrollment or randomisation of treatment in the present study</p> </li> <li> <p>Participation in another drug trial within 4 weeks prior to enrollment in this study or longer </p> </li> <li> <p>Admitted to hospital for diabetes mellitus (DM) related illness in past 12 weeks</p> </li> <li> <p>Not under physician's care for DM</p> </li> <li> <p>Physician responsible for DM care has indicated that DM is uncontrolled</p> </li> <li> <p>Physician responsible for DM care has not approved participation in the study</p> </li> <li> <p>Have not been on the same dose of DM medicine and/or diet for the 4 weeks prior to starting the study </p> </li> <li> <p>For thiazolidinediones (glitazones) this period should not be less than 8 weeks</p> </li> <li> <p>Taking insulin and the daily dose on one occasion in the past 4 weeks has been more than 10% above or below the mean dose in the preceding 4 weeks </p> </li> <li> <p>A low white blood cell count</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011804-bbs2-0004" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add‐on treatment of quetiapine for fibromyalgia: a pilot, randomized, double‐blind, placebo‐controlled 12‐week trial. Journal of Clinical Psychopharmacology2012;32:684‐7. ">Potvin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0014"> <li> <p>Female patients, older than 18 years</p> </li> <li> <p>Meeting the American College of Rheumatology criteria for the diagnosis of fibromyalgia</p> </li> <li> <p>Unsatisfactory response to their previous pharmacological treatment, defined as a score of 4 or greater on the pain severity item of the French version of the Fibromyalgia Impact Questionnaire (FIQ) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011804-list-0015"> <li> <p>Receiving an antipsychotic</p> </li> <li> <p>Pregnancy or females of childbearing potential without adequate contraception</p> </li> <li> <p>Risk of suicide</p> </li> <li> <p>Any Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I psychiatric disorder other than MDD </p> </li> <li> <p>Any clinically meaningful unstable, renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical illness and diabetes mellitus </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>DM: Diabetes mellitus<br/> DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition<br/> FIQ: Fibromyalgia Impact Questionnaire<br/> MDD: Major depressive disorder </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Inclusion and exclusion criteria of the studies included in the review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/full#CD011804-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011804-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antipsychotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 &gt;= 50% pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.02, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Drop‐out due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.06, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 &gt;= 30% pain reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.00, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.10, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.74, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.69, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 &gt;= 14% improvement of health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Drop‐out due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.23, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.06, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.05, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Substantial weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antipsychotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011804.pub2/references#CD011804-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011804.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011804-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011804-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011804-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011804-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011804-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011804\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011804\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011804\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011804\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011804\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011804.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011804.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011804.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011804.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011804.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715882749"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011804.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715882753"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011804.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d91efb8609368',t:'MTc0MDcxNTg4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 